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Background: Cytotoxic T-lymphocytes (CTLs) recognize 
complexes of short peptides with major histocompatibility 
complex (MHC) class I molecules. MHC molecules are 
polymorphic, and the products of different MHC alleles 
bind to different subsets of peptides. This is due to differ- 
ences in the shape of the peptide-binding groove on the 
surface of the MHC protein, especially the ‘pockets’ into 
which anchor residues at each end of the peptide fit. Non- 
peptidic ligands for class I molecules may be use&l clinically 
Results: By applying computer-aided design methods 
guided by X-ray structures, we designed and synthesized 
several MHC class I ligands, based on known peptide 
ligands, in which the tricyclic, aromatic compound 
phenanthridine replaced the central amino acids of 
the peptides. These semi-peptidic fluorescent ligands 
bound with high affinity and with allelic specificity to 
the peptide-binding groove of different MHC class I 
molecules, forming crystallizable complexes. 
Conclusions: Specificity for binding to different MHC 
class I molecules can be imparted to the common 
phenanthridine element by judicious choice of terminal. 
peptidic elements from either nonamer or decamer pep- 
tides. The phenanthridine-based ligands have a long 
bound half-life, as do antigenic peptides. 
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Introduction 
Major histocompatibility complex (MHC) proteins are 
central to the cellular immune response. There are two 
classes of MHC molecules; both present antigenic pep- 
tides on the surface of cells, but the different classes have 
different functions [l]. Class II MHC proteins, which are 
found on antigen-presenting cells, derive their peptidic 
ligands from proteolyzed, exogenous proteins and stimu- 
late helper T cells, activating an antibody response to the 
exogenous protein. Class I MHC proteins, which are 
found on virtually all cells, instead display peptides 
derived from proteins made within the cell. Peptides 
bind to MHC class I proteins in a groove on the upper 
surface of the protein, forming a composite surface (Fig. 
1) that can be recognized by the T-cell receptor (TCR). 
In the absence of peptide, MHC class I proteins are not 
stable, and do not survive on the cell surface. 
The MHC class I system appears to have evolved to allow 
the recognition and destruction of virally infected cells. 
When a cell is infected with a virus, peptides derived 
from viral proteins are displayed on the cell surface, 
where they can be recognized by circulating cytotoxic 
T-lymphocytes (CTLs), initiating a cytolytic response. 
However, unwanted or inappropriate TCR recognition of 
MHC-peptide complexes can initiate harmful responses, 
for example graft rejection and autoimmune disorders 
[2]. Graft rejection occurs because MHC class I molecules 
are highly polymorphic, so that-cells from grafted tissue 
that is not matched carry complexes of peptides with 
foreign MHC class I proteins, causing rejection. 
Autoimmunity results from a failure of the systems used 
by the body to ensure that T cells do not bind to com- 
plexes of self MHC with self peptide, and therefore do 
not attack self cells. 
The interaction between MHC class I molecules and 
their peptide ligands is now well understood. Peptides 
bound to different alleles of MHC class I molecules have 
Fig. 1. Structure of the Flu-NP peptide presented by the MHC 
molecule HLA-Aw68. The Flu-NP peptide (KTGGPIYKR) uses 
residues T2 and R9 (marked) as anchor residues. The vectors cho- 
sen for use in the search for possible ligands were from Ca of C4 
to N of C4 (solid arrow) and from Co of Y7 to CO of Y7 (hidden 
behind the ring of Y7, and therefore shown as a dotted arrow). 
*Corresponding authors. 
0 Current Biology Ltd ISSN 1074-5521 401 
402 Chemistry & Biology 1995, Vol 2 No 6 
(a) H 
r/ 
Veffi arrqmdiq to Two vector 
~sai~~~ CAVEAT 
backbone of MHC cbss I b&w& search A 
+ Example of one TRIAD 
(b) 
characteristic ‘anchor’ residues (Fig. l), often at their 
second (P2) and last positions, and are generally eight to 
ten residues long [3-6]. These anchor residues fit into 
specificity pockets in the binding groove that are found in 
class I proteins from both human [7-91 and mouse 
[lO,l 11. With their second and last residues fitted into 
pockets, peptides tend to arch away from the MHC 
molecule from about residues P4 to P7; these same 
residues have the greatest sequence variation (reviewed in 
[12]). Presumably, this central region is the most impor- 
tant element in the interaction with the TCR. Peptidic 
ligands to single subtypes of MHC molecules have been 
designed [13,14], but suffer from poor bio-availability in 
human sera [15]. We sought to replace the variable 
domains of MHC-binding peptides with a non-peptidic 
moiety, while retaining the ability of the terminal residues 
to bind to the ends of the peptide-binding groove in 
specific MHC class I proteins. 
Results and discussion 
From the refined X-ray structure of a peptide presented 
by the MHC class I molecule HLA-Aw68 [16], two 
bonds, along the peptide backbone and flanking the vari- 
able region, were identified as candidate parameters for 
ligand design (Fig. l).The two bonds, represented as two 
vectors (Fig. 2a), were used in a computational search 
[17,18] through a comprehensive database of 403 000 
Fig. 2. The design of a tricyclic linker. 
The initial search criteria consisted of 
two vectors, from two bonds along the 
peptide backbone (the C,-N bond of P4 
and the C,-carbonyl carbon bond of 
Pi’). A computational search through the 
TRIAD database of vectors from 
403 000 three-ring molecules revealed 
the 3,8-disubstituted tricyclic pattern. 
Although the suggestions were not 
planar, it was recognized that the 
chosen bonds could be joined by a 
planar 3,Sdisubstituted ring system. 
This was confirmed by computational 
modeling. Synthetic considerations 
guided the choice of starting material. 
(b) The sample structures shown illus- 
trate the structural diversity of the 
tricyclic molecules found by CAVEAT. 
three-ring molecules (TRIcyclics for Automated Design, 
TRIAD) ([19] and PA. Bartlett, G.A.W. & G. Lauri, 
unpublished work). Seventy-six tricyclics were identified 
that contain bonds with a vectorial relationship similar to 
that used in the search. After computational modeling of 
possible ligands (using the program Macromodel [20]), we 
turned our attention to the 3,%disubstituted phenan- 
thracene ring system, in part due to its rigid conforma- 
tion. An aza analog (phenanthridine) of this molecule was 
selected since a starting material for ligands incorporating 
this element, 3,8-diamino-6-phenyl-phenanthridine, is 
commercially available. A rapid and modular synthesis of 
the phenanthridine linker was accomplished by using an 
isocyanate of the penultimate residue [21], which reacted 
with phenanthridine site-specifically to yield a urea. Based 
upon NMR spectroscopic analysis, the reaction appears to 
occur at the more nucleophilic amino group at the 
3-position, although we note that a highly similar spacer 
element would result from isocyanate coupling at the 
&position. Solid-phase methods were used to complete 
the syntheses of the ligands (Fig. 3). 
The phenanthridine-based ligands bound to MHC mol- 
ecules and promoted their in vitro folding, despite the 
reduced conformational flexibility of the phenanthridine 
spacer. The yield of MHC complex was about 25 % 
based on the MHC heavy chain, comparable to that seen 
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Fig. 3. Synthesis of the phenanthridine- 
based ligands. Starting from a suitably 
protected version of the ligand’s pen- 
ultimate amino acid, the following 
conditions were used for subsequent 
transformations: (i) Triphosgene, i-Pr,NEt 
(N,N-diisopropylethylamine), THF (tet- 
rahydrofuran); (ii) 3,8-diamino-6-phen- 
ylphenanthridine, THF, 0 “C to room 
temperature; (iii) LiOH, THF:HzO (3:l); 
(iv) Fmoc-OSu (N-(9-Fluorenylmeth- 
oxycarbonyloxy)succinimide), 
dimethylformamide; (v) amino acid 
linked to solid support (50 mol %), 
HBTU (24 H-benzotriazol-1 -yl)-1 ,1,3,3- 
tetramethyluronium hexafluorophos- 
phate), HOBT (1 -hydroxybenzo- 
triazole), i-Pr,NEt, NMP (N-methyl- 
pyrrolidone); (vi) solid phase peptide 
synthesis. 
with peptides, and refolding was found to be dependent I-ligand complexes in gel filtration high-pressure liquid 
on the addition of the phenanthridine-based ligands, as it chromatography (HPLC) are similar to those of class 
is with peptides [22]. Retention times of the class I-antigenic peptide complexes. SDS-PAGE analysis of 
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Table 1. Structures of MHC class I ligands and their corresponding MHC class I subtypes. 
H 
MHC Parent peptide Amino terminus Carboxyl terminus Structure 
A2.1 
Aw68 
Hep-B 
Flu-M 
Flu-NP 
Human 
PheLeuProSer 
ClyLeuLeuGly 
LysThrClyGly 
GluValAlaAla 
SerVal 7 
ThrVal 8 
LysArg 9a 
Lyslys 9b 
Human GluValAla Lyslys 9c 
B27 Model ArgArglleAla LysArg 9d 
Each MHC class I molecule-ligand complex was assayed for its ability to fold by gel filtration chromatography, as described previ- 
ously 1221. Parent peptides are Hep-B: FLPSDFFPSV, from hepatitis B nucleocapsid [23]; Flu-M: GILGFVFTL, from influenza virus 
matrix, with modifications described previously [25]; Flu-NP: KTGGPIYKR, from influenza virus nucleoprotein [30]; Human: EVAP- 
PEYHRK [16] with P4A and R9K non-anchor substitutions; and Model: RRIKAITLK, a model peptide [29] that is modified in the pre- 
sent study with the following changes: K4A, L8K and K9R. Anchor residues are in bold face. 
the isolated complexes revealed the presence of both the 
heavy chain and the light chain of MHC class I mole- 
cules, &-microglobulin (&m), in the complex (data not 
shown).The class I molecule HLA-A2.1 complexed with 
the phenanthridine-based ligand corresponding to a 
peptide from hepatitis B virus (Table 1, entry 1, structure 
7) forms crystals nearly isomorphous to HLA- 
A2.1-peptide complexes [23]. X-ray diffraction studies 
(b) 
Fig. 4. Modified and unmodified MHC class I A2.1 ligands. (a) The X-ray crystal structure of the hepatitis B virus peptide (FLPSDFFPSV) 
bound to HLA-A2.1 1231. On the left, HLA residues are shown in gray, with the peptide in black; the right panel shows a space-filling 
model of the same structure. (b) Left, structure of the corresponding HLA-A2.1-phenanthridine-based ligand complex.The atoms drawn in 
black could be modeled with confidence into clear, continuous electron density. At the carboxyl terminus of the ligand the positions of the 
atoms drawn in gray are less certain because of breaks in the electron density of the ligand. Right, space-filling model of the same struc- 
ture. The poor electron density at the carboxyl terminus of the ligand in this structure may indicate some disorder of these ligand atoms. A 
large mosaic spread of the crystal (half width of 0.6 degrees) and the possibility of conformational heterogeneity of the ligand may con- 
tribute to this apparent disorder (E.J.C. & G.A.W., unpublished data). Experiments to grow and collect data from better crystals are ongoing. 
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Fig. 5. Dissociation of the hepatitis B peptide-based phenanthridine ligand from HLA-AZ.1 measured thermodynamically and 
kinetically. (a) Thermodynamic stability was measured as described previously [24-261, by monitoring the circular dichroism 
signal at 218 nm. The complex of HLA-AZ.1 and phenanthridine-based ligand has a lower melting temperature (T, = 56 “C) than 
does the complex with the unmodified peptide (T, = 68 ‘C) (FLPSDFFPSV). (b) Ligand dissociation measured by fluorescence. 
Error bars represent average error. 
show that the phenanthridine-based ligand bound in an 
orientation that is essentially identical to the parent 
peptide, with the central residues of the peptide replaced 
by the flat phenanthridine ring (Fig. 4). 
Thermodynamic stability, based upon circular dichroism- 
monitored denaturation temperatures (T,), has been 
measured for a number of complexes of peptides and 
MHC class I molecules [24-261. In general, higher 
melting temperatures correlate with higher binding affin- 
ity.Various peptide modifications, for example extending 
the length of the ligand t.o 11 amino acids, decrease the 
thermal stability of the MHC class I complex [27]. A 
phenanthridine ligand (7:) that is based on a hepatitis B 
peptide known to bind to the MHC class I molecule 
HLA-A2.1, also forms complexes with HLA-A2.1 that 
are stable at physiological temperatures but which exhibit 
somewhat decreased thermal stability (T, = 56 “C) in 
comparison to the parent peptide complex (T, = 68 “C) 
(Fig. 5a).This T, of 56 “C is within the normal range of 
class I MHC-peptide complexes. 
The fluorescence of the phenanthridine moiety was 
exploited to measure half lives for binding of phenan- 
thridine-based ligands to MHC molecules. When these 
ligands dissociate from the protein complex, the fluo- 
rescence intensity of the phenanthridine chromophore 
increases (Fig. 5b). The hepatitis B peptide-based, 
phenanthridine ligand (7) complex with HLA-A2.1 
showed a half life of 15 h at 37 “C (versus 25 h for the 
unmodified peptide complex, as measured indirectly by 
&rn dissociation [28]). This shorter half life of the 
phenanthridine-based ligand correlates with the lower 
melting temperature observed for HLA complexed with 
that ligand. 
The strategy of replacing variable regions was also suc- 
cessful in all other subtypes of MHC class I molecules 
examined (Table 1). The anchor residues of the ligand 
must match the requirements of the targeted MHC class 
I protein; mismatched anchor residues and MHC class I 
molecules did not result in folded complexes. Six 
phenanthridine-based ligands derived from five parent 
peptides were synthesized; as anticipated from the speci- 
ficities of the parent peptides, two were specific for 
HLA-A2.1, three for HLA-Aw68 and one for HLA- 
B27. For both HLA-A2.1 and HLA-Aw68, ligands 
based on decamer and nonamer peptides were synthe- 
sized; one ligand based on a nonamer was synthesized 
for HLA-B27. In each case, subtype-specific binding of 
ligand to MHC molecule was observed. The phenan- 
thridine spacer was used to replace three amino acids in 
three different nonameric peptides, four amino acids in 
two decameric peptides, and five amino acids in a 
decameric peptide (Table 1). The length of the planar 
spacer is -11.5 A. The X-ray crystal structures of all of 
the parent peptides complexed with their respective 
MHC ‘molecules have been determined previously 
([23,29] and E.J.C., unpublished data). The distance that 
the spacer replaces, measured in the complexes of the 
parent peptides with MHC molecules ([23,29,3!] and 
E.J.C., unpublished data), was between 8.1 A and 
12.9 A. This variation indicates that there is some 
accommodation in the position of the amino acids at 
the joints with the spacer, suggesting that the phenan- 
thridine spacer element can be made to bind in a 
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subtype-specific manner to many HLA molecules by 
equipping it with suitable terminal peptide elements. 
Significance 
The recognition step regulating CTL function 
involves a trimolecular complex ofTCR, MHC and 
the antigenic peptide. Since the antigenic peptide is 
relatively small, it is amenable to investigation 
using synthetic chemistry. The phenanthridine 
ligands based upon antigenic peptides reported 
here are a first step in this direction. 
A pharmacological antagonist that blocks CTL 
responses could be used to counter graft rejec- 
tion, and to treat autoimmune disorders [31]. 
Conversely, an agonist to enhance CTL response 
may be useful for treatment of tumors [32] or 
viral infections. The phenanthridine-based ligands 
are the first non-peptidic ligands reported to 
form structurally characterized complexes with 
MHC class I molecules. These complexes are 
stable at physiological temperatures and above, a 
prerequisite for effective competition with 
natural peptides.This study shows that the infor- 
mation gained from X-ray structures of MHC 
class I-peptide complexes, together with com- 
puter-based design techniques, can be used to 
design replacement elements that remove the 
requirement for long peptides as ligands to MHC 
class I molecules. In addition, the fluorescence of 
the phenanthridine spacer may prove valuable 
in biophysical studies of MHC-ligand and 
MHC-ligand-TCR complexes. 
Materials and methods 
Preparation of phenanthridine-based ligands 
Ligands were prepared by chemical synthesis as outlined in Fig. 
2 using standard laboratory procedures. All compounds were 
characterized by infrared spectroscopy, ‘H NMR, and fast atom 
bombardment (FAB) ‘mass spectroscopy or high resolution 
mass spectroscopy (HRMS). The first amino acid coupled to 
compounds 4, 5, 6a,b,c,d’ and all arginines were double 
coupled. Reverse phase HPLC (ligand dependent solvent gra- 
dient of 100:0 to 70:30 or 50:50 0.1 % trifluoroacetic acid in 
H20:acetonitrile) was used to purify the ligands. 
Synthesis of 621 
To a 0.1 M THF solution of a hydrochloride salt 3a 
(1.158 g, 3.5 mmol, 1 equiv), triphosgene (0.343 g, 
1.16 mmol, 0.33 equiv) inTHF (5 ml) was added. i-PrzNEt 
(3.1 ml, 17.5 mmol, 5 equiv) was added slowly, and the solu- 
tion was stirred for one hour at room temperature. Strong 
infrared absorbance at 2253 cm-l verified the presence of an 
isocyanate. This solution was cooled to 0 “C and added 
slowly via syringe to an ice-cold THF (20 ml) solution of 
3,8-diamino-6-phenyl-phenanthridine (1.0 g, 3.5 mmol, 
1 equiv), which was allowed to warm gradually to room 
temperature. Following overnight stirring, the solvent was 
rotary evaporated, and the oily residue redissolved in 
CH,Cl,. The solution was washed once with saturated 
NaHC03 and once with saturated NaCl and dried on an- 
hydrous sodium sulfate. Flash chromatography (95:5 
CH2C12:MeOH) was used to purify the compound 
(1.5861 g, 79.3 %). 
Characterization of ureo-phenanthridine 6.3 
‘H NMR (500 MHz, CDCl,): 6 8.30 (d,j = 14.0 Hz, lH, 
Ar), 8.22 (d,J = 13.9, lH,Ar), 7.65 (m, 2H,Ar), 7.48 (m, 3H, 
Ar), 7.37 (m, lH,Ar), 7.13 (m, 2H,Ar), 7.01 (m, lH,Ar), 
5.61 (br s, lH, NH(CO)NH-Ar), 4.76 (br m, IH, 
NH(CO)NH-Ar), 4.38 (m, lH, CHCO,CH,), 3.86 (br s, 
2H, NH,), 3.67 (s, 3H, CH,), 3.02 (m, 2H, NHCH&, 1.83 
(m, 2H, CHCH,), 1.42 (s, 9H, C(CI-I&), 1.25 (m, 4H, 
CH,);HRMS: m/z calc’d for C32H37N505 (M+H)+ 
572.2891, found 572.2873. 
Folding and purification of complexes of MHC class I 
molecules with ligands 
Denatured heavy chain and &rn were purified from an 
Escherichia coli expression system, as described previously [22]. 
After being individually diluted ten-fold in 8 M urea, heavy 
chain (final concentration of 1 PM) and &rn (final concen- 
tration of 2 PM) were added to 45 ml of 100 mM Tris 
(pH = 8), 400 mM L-arginine, 0.5 mM Na2EDTA, 5 mM 
reduced glutathione, 0.5 mM oxidized glutathione, contain- 
ing 50 PM phenanthridine-based ligand.After incubating for 
36 h at 10 “C, the solution was concentrated with a 
Centriprep-10 followed by a Centricon-10, to a volume of 
45 p.l.The concentrated protein was purified using gel filtra- 
tion HPLC with an eluent of 20 mM Tris (pH = 7.5) con- 
taining 150 mM NaCl and had a retention time of 18 
minutes (44 kD) in a Phenomenex Biosep SEC-S3000 
column. The 1.5 ml fraction containing the complex was 
concentrated to 45 p,l using a Centricon-10. 
Thermal stability measurements 
Circular dichroism experiments were conducted in 10 mM 
MOPS (pH = 7.5), in a 1 mm cell. Concentrations (from 3 to 
10 PM) of the complexes were determined spectrophoto- 
metrically (at 280 nm, E = 94 240 cm-’ M-‘).The Aviv 62DS 
spectropolarimeter was equipped with a thermoelectric 
temperature controller. 
Fluorescence kinetics 
Folded MHC class I-phenanthridine ligand complex (50 nM 
to 750 nM) was incubated at 37 “C and cooled to 10 “C before 
being excited at 310 nm and monitored for emission at 452 
nm. Cuvettes remained inside the Hitachi F-2000 fluorimeter 
during the course of each experiment. The buffer contained 
20 mM TRIS, 0.02 % NaN3, at pH = 7.5. 
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